DK2619208T3 - IMIDAZOTRIAZINON COMPOUNDS - Google Patents

IMIDAZOTRIAZINON COMPOUNDS Download PDF

Info

Publication number
DK2619208T3
DK2619208T3 DK11761793.6T DK11761793T DK2619208T3 DK 2619208 T3 DK2619208 T3 DK 2619208T3 DK 11761793 T DK11761793 T DK 11761793T DK 2619208 T3 DK2619208 T3 DK 2619208T3
Authority
DK
Denmark
Prior art keywords
mmol
trans
triazin
methylpyrrolidin
alkyl
Prior art date
Application number
DK11761793.6T
Other languages
Danish (da)
English (en)
Inventor
Amy Ripka
Gideon Shapiro
Richard Chesworth
Gerhard Koenig
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2619208T3 publication Critical patent/DK2619208T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK11761793.6T 2010-09-20 2011-09-20 IMIDAZOTRIAZINON COMPOUNDS DK2619208T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38469410P 2010-09-20 2010-09-20
PCT/US2011/052399 WO2012040230A1 (en) 2010-09-20 2011-09-20 Imidazotriazinone compounds

Publications (1)

Publication Number Publication Date
DK2619208T3 true DK2619208T3 (en) 2017-01-30

Family

ID=44720178

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11761793.6T DK2619208T3 (en) 2010-09-20 2011-09-20 IMIDAZOTRIAZINON COMPOUNDS

Country Status (16)

Country Link
US (3) US20120157458A1 (enExample)
EP (2) EP3181566A1 (enExample)
JP (2) JP5855109B2 (enExample)
CN (1) CN103313988B (enExample)
AR (1) AR083058A1 (enExample)
AU (2) AU2011305568B2 (enExample)
BR (1) BR112013008140A8 (enExample)
CA (1) CA2811714C (enExample)
DK (1) DK2619208T3 (enExample)
ES (1) ES2610360T3 (enExample)
MX (1) MX2013003093A (enExample)
PL (1) PL2619208T3 (enExample)
RU (1) RU2603140C2 (enExample)
TW (1) TWI541244B (enExample)
UY (1) UY33616A (enExample)
WO (1) WO2012040230A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2619208T3 (en) * 2010-09-20 2017-01-30 Ironwood Pharmaceuticals Inc IMIDAZOTRIAZINON COMPOUNDS
EP2906562B1 (en) * 2011-10-10 2016-10-05 H. Lundbeck A/S Pde9i with imidazo pyrazinone backbone
AP2014007820A0 (en) 2012-01-26 2014-07-31 Lundbeck & Co As H PDE9 inhibitors with imidazo triazinone backbone
HK1206726A1 (en) * 2012-03-19 2016-01-15 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
CN102786525B (zh) 2012-08-08 2014-12-17 中山大学 N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
CN104884449A (zh) 2012-10-31 2015-09-02 拜尔农作物科学股份公司 作为害虫防治剂的新的杂环化合物
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
US20180044343A1 (en) * 2015-03-16 2018-02-15 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic imidazolo derivative
US20160311831A1 (en) * 2015-04-22 2016-10-27 H. Lundbeck A/S Imidazotriazinones as PDE1 Inhibitors
JO3627B1 (ar) * 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
HRP20210543T1 (hr) 2015-07-07 2021-05-14 H. Lundbeck A/S Inhibitori pde9 s imidazo triazinonskom okosnicom i imidazo pirazinonskom okosnicom za liječenje perifernih bolesti
WO2017070293A1 (en) * 2015-10-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Phosphodiesterase 9 inhibitor and levodopa therapy
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
WO2018009424A1 (en) 2016-07-06 2018-01-11 Imara, Inc. Pde9 inhibitors for treatment of peripheral diseases
CN109843884B (zh) 2016-10-18 2022-03-04 H.隆德贝克有限公司 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮
HRP20201326T1 (hr) 2016-10-28 2020-11-27 H. Lundbeck A/S Kombinacijska liječenja koja sadrže imidazopirazinone za liječenje psihijatrijskih i/ili kognitivnih poremećaja
AU2017350477A1 (en) 2016-10-28 2019-04-18 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
CA3064004A1 (en) * 2017-05-26 2018-11-29 Imara Inc. Methods of making and using pde9 inhibitors
CN112469413B (zh) 2018-05-25 2024-01-12 伊马拉公司 6-[(3s,4s)-4-甲基-1-(嘧啶-2-基甲基)吡咯烷-3-基]-3-四氢吡喃-4-基-7h-咪唑并[1,5-a]吡嗪-8-酮的一水合物和结晶形态
EP3843737A4 (en) 2018-08-31 2022-06-01 Imara Inc. PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
WO2020102374A1 (en) * 2018-11-14 2020-05-22 The Board Of Trustees Of The Leland Stanford Junior University Targeting of makap-pde4d3 complexes in neurodegenerative disease
KR102712818B1 (ko) 2018-12-06 2024-09-30 한국화학연구원 Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도
KR20220086607A (ko) * 2019-10-21 2022-06-23 에스케이바이오팜 주식회사 발달 장애의 예방, 경감 또는 치료를 위한 이미다조피리미딘 또는 이미다조트리아진 화합물의 용도
CN112724079A (zh) * 2021-02-04 2021-04-30 康化(上海)新药研发有限公司 一种6-甲氧基吡啶甲酸甲酯的合成方法
GB2632307A (en) * 2023-08-02 2025-02-05 Duke Street Bio Ltd PARP1 inhibitor compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
DE19750085A1 (de) * 1997-11-12 1999-05-20 Bayer Ag 2-Phenyl-substituierte Imidazotriazinone
PT1049695E (pt) 1997-11-12 2002-07-31 Bayer Ag Imidazotriazinonas 2-fenil substituidas enquanto inibidores de fosfodiesterase
US7087605B2 (en) 2001-06-01 2006-08-08 Bayer Aktiengesellschaft 5-Ethyl-imidazotriazinones
GB0113343D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel Heterocycles 2
HUP0401998A2 (hu) * 2001-11-02 2005-01-28 Pfizer Products Inc., PDE9 inhibitorok alkalmazása olyan gyógyszer előállítására, amellyel inzulin-rezisztencia szindróma és 2-es típusú diabétesz kezelhető
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US20060264624A1 (en) 2005-05-20 2006-11-23 Alexander Heim-Riether Methods for synthesizing imidazotriazinones
WO2007000655A2 (en) 2005-06-28 2007-01-04 Orchid Research Laboratories Limited Novel pyrazolopyrimidinone derivatives
AU2008249750B2 (en) * 2007-05-11 2011-07-14 Pfizer Inc. Amino-heterocyclic compounds
CN102131801B (zh) 2008-06-25 2015-04-08 福拉姆医药股份有限公司 1,2-二取代的杂环化合物
DK2619208T3 (en) 2010-09-20 2017-01-30 Ironwood Pharmaceuticals Inc IMIDAZOTRIAZINON COMPOUNDS
AP2014007820A0 (en) 2012-01-26 2014-07-31 Lundbeck & Co As H PDE9 inhibitors with imidazo triazinone backbone
HK1206726A1 (en) 2012-03-19 2016-01-15 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds

Also Published As

Publication number Publication date
AR083058A1 (es) 2013-01-30
WO2012040230A1 (en) 2012-03-29
BR112013008140A8 (pt) 2018-04-03
CA2811714A1 (en) 2012-03-29
US20140330014A1 (en) 2014-11-06
CN103313988A (zh) 2013-09-18
UY33616A (es) 2012-04-30
EP2619208A1 (en) 2013-07-31
EP2619208B1 (en) 2016-11-09
US9540380B2 (en) 2017-01-10
AU2016200970A1 (en) 2016-03-03
BR112013008140A2 (pt) 2017-12-05
RU2603140C2 (ru) 2016-11-20
RU2013118362A (ru) 2014-10-27
AU2011305568A1 (en) 2013-04-04
PL2619208T3 (pl) 2017-03-31
ES2610360T3 (es) 2017-04-27
US20120157458A1 (en) 2012-06-21
JP5855109B2 (ja) 2016-02-09
TWI541244B (zh) 2016-07-11
AU2011305568B2 (en) 2015-12-10
TW201217381A (en) 2012-05-01
JP2013540755A (ja) 2013-11-07
US20170152265A1 (en) 2017-06-01
MX2013003093A (es) 2013-10-28
CA2811714C (en) 2017-11-21
EP3181566A1 (en) 2017-06-21
CN103313988B (zh) 2016-06-08
JP2016104747A (ja) 2016-06-09
HK1187908A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
DK2619208T3 (en) IMIDAZOTRIAZINON COMPOUNDS
US9969742B2 (en) Imidazotriazinone compounds
EP3535267B1 (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
EP3535268B1 (en) [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
JP2024541758A (ja) Egfrキナーゼの分解のための化合物
WO2018083103A1 (en) [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
HK1187908B (en) Imidazotriazinone compounds
HK1234039A1 (en) Imidazotriazinone compounds
HK40058692A (en) 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds